Логотип Freelancer
Увійти Реєстрація
Опублікувати проект
ВІДКРИЙТЕ ДЛЯ СЕБЕ
Article Writing
Business Plans
Data Entry
Finance
Research Writing
Фото на обкладинці профілю
Тепер ви підписані на
Помилка підписки на користувача.
Цей користувач не дозволяє слідувати за ним.
Ви вже слідуєте за цим користувачем.
Ваш членський план дозволяє мати не більше 0 підписок. Покращити рівень членства можна тут.
Успішно відписалися від
Помилка під час скасування підписки на користувача.
Ви успішно рекомендували
Помилка рекомендування користувача.
Щось пішло не так. Будь ласка, оновіть сторінку та повторіть спробу.
Електронну адресу успішно верифіковано.
Аватарка користувача

Corey D.

@coreyd5

0,0
0
0,0
0,0
0%

Helping build tech-enabled healthcare companies

$50 USD / год.
・
Прапор
United States (11:45 пп)
・
На сайті з листопада 30, 2024
$50 USD / год.
・
Innovative and results-driven executive with extensive experience in healthcare-focused leadership, corporate development, mergers and acquisitions (M&A), and strategic consulting. Proven track record of driving growth for companies ranging from startups to publicly traded organizations. Adept at identifying undervalued opportunities, building partnerships, and managing complex transactions. Expertise in business development, DTC marketing, operations and market research.
Верифікації
Freelancer Data Entry Clerks United States
Переглянути всіх Data Entry Clerks в United States

Портфоліо

Портфоліо

12386338
Since founding Medically Modern Inc. in June 2023, I have built a company that provides diabetic supplies to patients nationwide. As the active CEO and sole founder, I have overseen all aspects of the business, which has scaled to a subscription revenue model, currently reaching an annual recurring revenue (ARR) of $2M. We have successfully credentialed and contracted with all major payors, submitting claims directly to them for payment. Additionally, we employ an omnichannel marketing strategy to acquire patients, integrating various platforms and touchpoints to engage with our target audience effectively. With a patient-first approach, we continue to expand and grow, focused on delivering essential diabetic supplies to those in need and enhancing the healthcare experience for our users.
Founded Diabetes Technology Company
12386321
The business development work I conducted across these companies reflects a consistent focus on driving strategic growth, executing high-impact transactions, and building value through partnerships, joint ventures, and M&A. Below is an overview of my contributions: Semler Scientific: 1) Led all initiatives to identify acquisition targets, partnerships, and joint ventures. 2) Conducted extensive market research and valuation analysis, uncovering high-impact growth opportunities. NightHawk Biosciences, Inc: Directed strategic contracting for financing commercial biodefense assets and securing government contracts. Scorpius BioManufacturing: Oversaw business development for a large-molecule CDMO, forging strategic relationships with pharmaceutical companies to expand market reach and revenue. iSpecimen: 1) Led M&A initiatives, joint ventures, and partnerships to foster inorganic growth. 2) Identified and implemented cost-saving measures and operational strategies for profitabi
Led BD For 6 Healthcare Companies
The business development work I conducted across these companies reflects a consistent focus on driving strategic growth, executing high-impact transactions, and building value through partnerships, joint ventures, and M&A. Below is an overview of my contributions: Semler Scientific: 1) Led all initiatives to identify acquisition targets, partnerships, and joint ventures. 2) Conducted extensive market research and valuation analysis, uncovering high-impact growth opportunities. NightHawk Biosciences, Inc: Directed strategic contracting for financing commercial biodefense assets and securing government contracts. Scorpius BioManufacturing: Oversaw business development for a large-molecule CDMO, forging strategic relationships with pharmaceutical companies to expand market reach and revenue. iSpecimen: 1) Led M&A initiatives, joint ventures, and partnerships to foster inorganic growth. 2) Identified and implemented cost-saving measures and operational strategies for profitabi
Led BD For 6 Healthcare Companies
The business development work I conducted across these companies reflects a consistent focus on driving strategic growth, executing high-impact transactions, and building value through partnerships, joint ventures, and M&A. Below is an overview of my contributions: Semler Scientific: 1) Led all initiatives to identify acquisition targets, partnerships, and joint ventures. 2) Conducted extensive market research and valuation analysis, uncovering high-impact growth opportunities. NightHawk Biosciences, Inc: Directed strategic contracting for financing commercial biodefense assets and securing government contracts. Scorpius BioManufacturing: Oversaw business development for a large-molecule CDMO, forging strategic relationships with pharmaceutical companies to expand market reach and revenue. iSpecimen: 1) Led M&A initiatives, joint ventures, and partnerships to foster inorganic growth. 2) Identified and implemented cost-saving measures and operational strategies for profitabi
Led BD For 6 Healthcare Companies
12386307
The acquisition of Elusys Therapeutics by Heat Biologics (now NightHawk Biosciences) was a pivotal step in expanding its presence in the biodefense sector. As the lead M&A consultant and advisor, I was responsible for identifying Elusys as a high-value target, conducting financial due diligence, and managing the orchestration of third-party stakeholders. This included analyzing Elusys' revenue streams from $350M+ in U.S. government contracts, mitigating risks tied to these agreements, and ensuring regulatory compliance. I facilitated deal negotiations between Heat Biologics’ board, Elusys’ advisors, and legal counsel, ensuring favorable terms with no stock or warrants issued. Post-acquisition, I oversaw integration planning, including migrating manufacturing of ANTHIM®—a critical anthrax treatment—to NightHawk’s new Kansas facility. The transaction bolstered NightHawk’s capabilities, enhanced operating synergies, and strengthened its RapidVax® platform for addressing emerging biolo
Led Acquistion Biodefense Biologic
12386294
As the Chief Business Officer of LifeMD (NASDAQ: LFMD) I led the launch of LifeMD’s virtual care division, overseeing its development from inception to launch. My role included orchestrating the efforts of multiple teams, such as marketing, finance, development, and operations, ensuring that every aspect of the project was seamlessly integrated. From conceptualizing the platform to coordinating a phased rollout, I ensured that every piece was tied together into a cohesive and fluid operation, enabling the division to launch on time and succesfully. At launch, LifeMD’s virtual care platform delivers 24/7 access to affordable, patient-centric care nationwide. Patients were paired with primary care physicians and medical teams, gaining unlimited messaging, on-demand consultations, and discounted prescription medications. By streamlining the onboarding process and utilizing telehealth technology, the platform provided patients with quick, convenient access to their personalized care team.
Telehealth Business Division Launch
As the Chief Business Officer of LifeMD (NASDAQ: LFMD) I led the launch of LifeMD’s virtual care division, overseeing its development from inception to launch. My role included orchestrating the efforts of multiple teams, such as marketing, finance, development, and operations, ensuring that every aspect of the project was seamlessly integrated. From conceptualizing the platform to coordinating a phased rollout, I ensured that every piece was tied together into a cohesive and fluid operation, enabling the division to launch on time and succesfully. At launch, LifeMD’s virtual care platform delivers 24/7 access to affordable, patient-centric care nationwide. Patients were paired with primary care physicians and medical teams, gaining unlimited messaging, on-demand consultations, and discounted prescription medications. By streamlining the onboarding process and utilizing telehealth technology, the platform provided patients with quick, convenient access to their personalized care team.
Telehealth Business Division Launch
As the Chief Business Officer of LifeMD (NASDAQ: LFMD) I led the launch of LifeMD’s virtual care division, overseeing its development from inception to launch. My role included orchestrating the efforts of multiple teams, such as marketing, finance, development, and operations, ensuring that every aspect of the project was seamlessly integrated. From conceptualizing the platform to coordinating a phased rollout, I ensured that every piece was tied together into a cohesive and fluid operation, enabling the division to launch on time and succesfully. At launch, LifeMD’s virtual care platform delivers 24/7 access to affordable, patient-centric care nationwide. Patients were paired with primary care physicians and medical teams, gaining unlimited messaging, on-demand consultations, and discounted prescription medications. By streamlining the onboarding process and utilizing telehealth technology, the platform provided patients with quick, convenient access to their personalized care team.
Telehealth Business Division Launch
12386244
Anchored a $15M equity followed by leading the uplisting efforts to get a DTC telehealth company onto the NASDAQ. Individually raised $3.5M of the $15M through a Special Purpose Vehicle (SPV) via the Healthcare-focused Hedge Fund I founded called Paradigm Opportunities. Efforts included developing the investment thesis, raising capital from 20 LPs, forming the SPV, working alongside management to ensure NASDAQ compliance and monitoring the investment.
Lead Investor In $15M Equity Raise
12386338
Since founding Medically Modern Inc. in June 2023, I have built a company that provides diabetic supplies to patients nationwide. As the active CEO and sole founder, I have overseen all aspects of the business, which has scaled to a subscription revenue model, currently reaching an annual recurring revenue (ARR) of $2M. We have successfully credentialed and contracted with all major payors, submitting claims directly to them for payment. Additionally, we employ an omnichannel marketing strategy to acquire patients, integrating various platforms and touchpoints to engage with our target audience effectively. With a patient-first approach, we continue to expand and grow, focused on delivering essential diabetic supplies to those in need and enhancing the healthcare experience for our users.
Founded Diabetes Technology Company
12386321
The business development work I conducted across these companies reflects a consistent focus on driving strategic growth, executing high-impact transactions, and building value through partnerships, joint ventures, and M&A. Below is an overview of my contributions: Semler Scientific: 1) Led all initiatives to identify acquisition targets, partnerships, and joint ventures. 2) Conducted extensive market research and valuation analysis, uncovering high-impact growth opportunities. NightHawk Biosciences, Inc: Directed strategic contracting for financing commercial biodefense assets and securing government contracts. Scorpius BioManufacturing: Oversaw business development for a large-molecule CDMO, forging strategic relationships with pharmaceutical companies to expand market reach and revenue. iSpecimen: 1) Led M&A initiatives, joint ventures, and partnerships to foster inorganic growth. 2) Identified and implemented cost-saving measures and operational strategies for profitabi
Led BD For 6 Healthcare Companies
The business development work I conducted across these companies reflects a consistent focus on driving strategic growth, executing high-impact transactions, and building value through partnerships, joint ventures, and M&A. Below is an overview of my contributions: Semler Scientific: 1) Led all initiatives to identify acquisition targets, partnerships, and joint ventures. 2) Conducted extensive market research and valuation analysis, uncovering high-impact growth opportunities. NightHawk Biosciences, Inc: Directed strategic contracting for financing commercial biodefense assets and securing government contracts. Scorpius BioManufacturing: Oversaw business development for a large-molecule CDMO, forging strategic relationships with pharmaceutical companies to expand market reach and revenue. iSpecimen: 1) Led M&A initiatives, joint ventures, and partnerships to foster inorganic growth. 2) Identified and implemented cost-saving measures and operational strategies for profitabi
Led BD For 6 Healthcare Companies
The business development work I conducted across these companies reflects a consistent focus on driving strategic growth, executing high-impact transactions, and building value through partnerships, joint ventures, and M&A. Below is an overview of my contributions: Semler Scientific: 1) Led all initiatives to identify acquisition targets, partnerships, and joint ventures. 2) Conducted extensive market research and valuation analysis, uncovering high-impact growth opportunities. NightHawk Biosciences, Inc: Directed strategic contracting for financing commercial biodefense assets and securing government contracts. Scorpius BioManufacturing: Oversaw business development for a large-molecule CDMO, forging strategic relationships with pharmaceutical companies to expand market reach and revenue. iSpecimen: 1) Led M&A initiatives, joint ventures, and partnerships to foster inorganic growth. 2) Identified and implemented cost-saving measures and operational strategies for profitabi
Led BD For 6 Healthcare Companies
12386307
The acquisition of Elusys Therapeutics by Heat Biologics (now NightHawk Biosciences) was a pivotal step in expanding its presence in the biodefense sector. As the lead M&A consultant and advisor, I was responsible for identifying Elusys as a high-value target, conducting financial due diligence, and managing the orchestration of third-party stakeholders. This included analyzing Elusys' revenue streams from $350M+ in U.S. government contracts, mitigating risks tied to these agreements, and ensuring regulatory compliance. I facilitated deal negotiations between Heat Biologics’ board, Elusys’ advisors, and legal counsel, ensuring favorable terms with no stock or warrants issued. Post-acquisition, I oversaw integration planning, including migrating manufacturing of ANTHIM®—a critical anthrax treatment—to NightHawk’s new Kansas facility. The transaction bolstered NightHawk’s capabilities, enhanced operating synergies, and strengthened its RapidVax® platform for addressing emerging biolo
Led Acquistion Biodefense Biologic
12386294
As the Chief Business Officer of LifeMD (NASDAQ: LFMD) I led the launch of LifeMD’s virtual care division, overseeing its development from inception to launch. My role included orchestrating the efforts of multiple teams, such as marketing, finance, development, and operations, ensuring that every aspect of the project was seamlessly integrated. From conceptualizing the platform to coordinating a phased rollout, I ensured that every piece was tied together into a cohesive and fluid operation, enabling the division to launch on time and succesfully. At launch, LifeMD’s virtual care platform delivers 24/7 access to affordable, patient-centric care nationwide. Patients were paired with primary care physicians and medical teams, gaining unlimited messaging, on-demand consultations, and discounted prescription medications. By streamlining the onboarding process and utilizing telehealth technology, the platform provided patients with quick, convenient access to their personalized care team.
Telehealth Business Division Launch
As the Chief Business Officer of LifeMD (NASDAQ: LFMD) I led the launch of LifeMD’s virtual care division, overseeing its development from inception to launch. My role included orchestrating the efforts of multiple teams, such as marketing, finance, development, and operations, ensuring that every aspect of the project was seamlessly integrated. From conceptualizing the platform to coordinating a phased rollout, I ensured that every piece was tied together into a cohesive and fluid operation, enabling the division to launch on time and succesfully. At launch, LifeMD’s virtual care platform delivers 24/7 access to affordable, patient-centric care nationwide. Patients were paired with primary care physicians and medical teams, gaining unlimited messaging, on-demand consultations, and discounted prescription medications. By streamlining the onboarding process and utilizing telehealth technology, the platform provided patients with quick, convenient access to their personalized care team.
Telehealth Business Division Launch
As the Chief Business Officer of LifeMD (NASDAQ: LFMD) I led the launch of LifeMD’s virtual care division, overseeing its development from inception to launch. My role included orchestrating the efforts of multiple teams, such as marketing, finance, development, and operations, ensuring that every aspect of the project was seamlessly integrated. From conceptualizing the platform to coordinating a phased rollout, I ensured that every piece was tied together into a cohesive and fluid operation, enabling the division to launch on time and succesfully. At launch, LifeMD’s virtual care platform delivers 24/7 access to affordable, patient-centric care nationwide. Patients were paired with primary care physicians and medical teams, gaining unlimited messaging, on-demand consultations, and discounted prescription medications. By streamlining the onboarding process and utilizing telehealth technology, the platform provided patients with quick, convenient access to their personalized care team.
Telehealth Business Division Launch
12386244
Anchored a $15M equity followed by leading the uplisting efforts to get a DTC telehealth company onto the NASDAQ. Individually raised $3.5M of the $15M through a Special Purpose Vehicle (SPV) via the Healthcare-focused Hedge Fund I founded called Paradigm Opportunities. Efforts included developing the investment thesis, raising capital from 20 LPs, forming the SPV, working alongside management to ensure NASDAQ compliance and monitoring the investment.
Lead Investor In $15M Equity Raise
Зміни збережено
0.0 · 0 Reviews
Відгуки
Тут немає відгуків для перегляду!
Запрошення успішно надіслане!
Дякуємо! Ми надіслали на вашу електронну пошту посилання для отримання безкоштовного кредиту.
Під час надсилання електронного листа сталася помилка. Будь ласка, спробуйте ще раз.
Логотип Freelancer Ukraine / Українська
Допомога та підтримка
 Фрілансер
Категорії Проекти Конкурси Фрілансери Enterprise Розробка на основі ШІ Членство Програма "Бажаний Фрілансер" Керування проектами Місцеві роботиPhoto Anywhere Вітрина API для розробників Верифікація Desktop App
 Про нас
Про нас Як це працює Безпека Інвестиції Мапа сайту Історії Новини Команда Нагороди Прес-релізи Вакансії
 Умови
Політика конфіденційності Умови користування Політика захисту авторських прав Правила поведінки Комісії і тарифи
 Партнери
Escrow.comLoadshiftWarrior Forum
 Застосунки
Логотип Apple App StoreЛоготип Google Play
Не вдалося скопіювати в буфер обміну. Будь ласка, налаштуйте дозволи та повторіть спробу.
Скопійовано в буфер обміну.
Зареєстрованих користувачів Загальна кількість опублікованих робіт
Freelancer ® is a registered Trademark of Freelancer Technology Pty Limited (ACN 142 189 759)
Copyright © 2025 Freelancer Technology Pty Limited (ACN 142 189 759)
Завантажуємо для перегляду
Дозвіл на визначення геолокації надано.
Ваш сеанс входу закінчився, і сеанс було закрито. Будь ласка, увійдіть знову.